Tyr282
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr282  -  BTLA (human)

Site Information
VKEAPtEyASICVRS   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 463077
Associated spectra:  2 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 2 , 3 , 4 , 5 , 6 , 7 ) , mutation of modification site ( 1 )
Disease tissue studied:
leukemia ( 1 ) , T cell leukemia ( 1 ) , lung cancer ( 2 , 3 , 4 , 5 ) , non-small cell lung cancer ( 2 , 3 , 4 , 5 ) , non-small cell lung adenocarcinoma ( 2 , 3 , 4 , 5 ) , lymphoma ( 1 ) , Burkitt's lymphoma ( 1 ) , multiple myeloma ( 7 ) , thymic carcinoma ( 6 )
Relevant cell line - cell type - tissue:
Jurkat (T lymphocyte) ( 1 ) , KMS-18 (B lymphocyte) ( 7 ) , lung ( 2 , 3 , 4 , 5 ) , Raji (B lymphocyte) ( 1 ) , thymus ( 6 )

Upstream Regulation
Kinases, in vitro:
Lck (human) ( 1 )

Downstream Regulation
Effects of modification on BTLA:
phosphorylation ( 1 )
Effects of modification on biological processes:
signaling pathway regulation ( 1 )

References 

1

Xu X, et al. (2020) PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2. J Cell Biol 219
32437509   Curated Info

2

Ren H (2011) CST Curation Set: 11772; Year: 2011; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

3

Ren H (2011) CST Curation Set: 11773; Year: 2011; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

4

Ren H (2011) CST Curation Set: 11774; Year: 2011; Biosample/Treatment: cell line, RP91/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

5

Ren H (2011) CST Curation Set: 11775; Year: 2011; Biosample/Treatment: cell line, RP92/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

6

Li Y (2011) CST Curation Set: 10460; Year: 2011; Biosample/Treatment: tissue, thymus/untreated; Disease: thymic carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

7

Gu T (2005) CST Curation Set: 874; Year: 2005; Biosample/Treatment: cell line, KMS-18/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info